CGRP as the target of new migraine therapies — successful translation from bench to clinic
@article{Edvinsson2018CGRPAT, title={CGRP as the target of new migraine therapies — successful translation from bench to clinic}, author={L. Edvinsson and K. Haanes and K. Warfvinge and D. Krause}, journal={Nature Reviews Neurology}, year={2018}, volume={14}, pages={338-350} }
Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few… CONTINUE READING
Figures, Tables, and Topics from this paper
Paper Mentions
Observational Clinical Trial
Migraine is the 2nd most disabling neurological disease. It affects 14.7% of the population
(children and adults) of whom 80% are female. In the EU, the total annual cost of migraine is… Expand
Conditions | Migraine |
---|
News Article
News Article
News Article
News Article
News Article
News Article
218 Citations
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
- Medicine
- Revue neurologique
- 2020
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
- Medicine
- Front. Pharmacol.
- 2019
- 20
- PDF
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
- Medicine
- Expert review of neurotherapeutics
- 2020
- 7
CGRP-based Migraine Therapeutics: How Might They Work, Why So Safe, and What Next?
- Medicine
- ACS pharmacology & translational science
- 2019
- 9
Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class
- Medicine
- Headache
- 2019
- 29
Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
- Medicine
- The journal of headache and pain
- 2019
- 8
Monoclonal antibodies for the prevention of migraine
- Medicine
- Expert opinion on biological therapy
- 2019
- 11
- Highly Influenced
Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models
- Medicine
- Cephalalgia : an international journal of headache
- 2019
- 11
References
SHOWING 1-10 OF 200 REFERENCES
Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review
- Medicine
- Clinical neuropharmacology
- 2017
- 27
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
- Chemistry, Medicine
- British journal of clinical pharmacology
- 2015
- 118
Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists
- Medicine
- Expert opinion on therapeutic targets
- 2007
- 19
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
- Medicine
- Therapeutic advances in neurological disorders
- 2010
- 78
CGRP-receptor antagonism in migraine treatment.
- Medicine
- CNS & neurological disorders drug targets
- 2007
- 37
Therapeutic antibodies against CGRP or its receptor.
- Medicine
- British journal of clinical pharmacology
- 2015
- 73
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
- Chemistry, Medicine
- Journal of medicinal chemistry
- 2014
- 43
CGRP and its receptors provide new insights into migraine pathophysiology
- Medicine
- Nature Reviews Neurology
- 2010
- 339